The results of this study reveal for the first time that acute oral intake of mitochondrial-targeted antioxidant (MitoQ, 80 mg) is effective for improving vascular endothelial function and superoxide dismutase in patients with peripheral artery disease (PAD). Acute MitoQ intake is also effective for improving maximal walking capacity and delaying the onset of claudication in patients with PAD. These findings suggest that the acute oral intake of MitoQ-mediated improvements in vascular mitochondria play a pivotal role for improving endothelial function, the redox environment, and skeletal muscle performance in PAD.

中文翻译：

---

急性线粒体抗氧化剂摄入可改善外周动脉疾病患者的内皮功能、抗氧化酶活性和运动耐量

这项研究的结果首次揭示，急性口服线粒体靶向抗氧化剂（MitoQ，80 mg）可有效改善外周动脉疾病（PAD）患者的血管内皮功能和超氧化物歧化酶。急性摄入 MitoQ 还可有效提高 PAD 患者的最大步行能力并延缓跛行的发生。这些发现表明，急性口服 MitoQ 介导的血管线粒体改善对于改善 PAD 中的内皮功能、氧化还原环境和骨骼肌性能发挥着关键作用。